Axsome Therapeutics (AXSM) Misses Q2 EPS by 30c

Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($1.54), $0.30 worse than the analyst estimate of ($1.24). Revenue for the quarter came in at $46.01 million versus the consensus estimate of $40.89 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Assurant (AIZ) is Piper Sandler's Weekly Focus Idea
• C.H. Robinson acquires DeSpir Logistics for $75 million